Mobocertinib

SKU: orb1299174

Description

Mobocertinib (TAK-788) is a selective, small-molecule EGFR inhibitor developed as an antineoplastic agent. It is utilized in preclinical and clinical research, particularly for targeting EGFR exon 20 insertion mutations in non-small cell lung cancer models, both in vitro and in vivo.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1847461-43-1
• MW: 585.7
• Purity: 99.72%
• Formula: C₃₂H₃₉N₇O₄
• SMILES: COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1ncc(C(=O)OC(C)C)c(n1)-c1cn(C)c2ccccc12
• Target: EGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (1.71 mM);DMSO:5 mg/mL (8.54 mM)

Bioactivity

• Target IC50:
  EGFR (WT):35 nM (IC50)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CUTO14, AP32788, AP-32788, AP 32788, A431, Mobocertinib, NSCLC, LU0387, Inhibitor, inhibit, ErbB-1, Epidermal growth factor receptor, EGFRex20ins, EGFR, H1975, HER1, HCC4011, HCC827, tak788, TAK-788, TAK 788

Compound Identifiers

PubChem CID

118607832